Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

@article{Bissett2004PhaseIA,
  title={Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)},
  author={Donald Bissett and Jim Cassidy and Johan S de Bono and F Muirhead and Muhammad Main and Lesley G. Robson and Daniela Fraier and M L Magn{\`e} and Cinzia Pellizzoni and M G Porro and Riccardo Spinelli and William Speed and Christopher J. Twelves},
  journal={British Journal of Cancer},
  year={2004},
  volume={91},
  pages={50 - 55}
}
Polymeric cytotoxic conjugates are being developed with the aim of preferential delivery of the anticancer agent to tumour. MAG-CPT comprises the topoisomerase I inhibitor camptothecin linked to a water-soluble polymeric backbone methacryloylglycynamide (average molecular weight 18 kDa, 10% CPT by weight). It was administered as a 30-min infusion once every 4 weeks to patients with advanced solid malignancies. The objectives of our study were to determine the maximum tolerated dose, dose… CONTINUE READING